Lexeo Therapeutics, Inc. Statistics
Want to see LXEO full AI Analyst Report?
Lexeo Therapeutics, Inc. (LXEO) Stock Statistics & Valuation Metrics
Total Valuation
Lexeo Therapeutics, Inc. has a market cap or net worth of $237.23M. The enterprise value is $193.70M.
- Market Cap
- $237.23M
- Enterprise Value
- $193.70M
Share Statistics
Lexeo Therapeutics, Inc. has 82,088,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 82,088,160
- Owned by Insiders
- 1.13%
- Owned by Institutions
- 23.60%
Financial Efficiency
Lexeo Therapeutics, Inc.’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -42.92%.
- Return on Equity (ROE)
- -0.41
- Return on Assets (ROA)
- -0.37
- Return on Invested Capital (ROIC)
- -42.92%
- Return on Capital Employed (ROCE)
- -0.43
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.59M
- Employee Count
- 63
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lexeo Therapeutics, Inc. is -2.66. Lexeo Therapeutics, Inc.’s PEG ratio is -0.02.
- PE Ratio
- -2.66
- PS Ratio
- 0.00
- PB Ratio
- 1.11
- Price to FCF
- -2.83
- Price to Operating Cash Flow
- -2.97
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Lexeo Therapeutics, Inc. had revenue of 0 and earned -99.96M in profits. Earnings per share was -1.86.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -109.26M
- Pretax Income
- -99.96M
- Net Income
- -99.96M
- EBITDA
- -97.68M
- Earnings Per Share (EPS)
- -1.86
Cash Flow
In the last 12 months, operating cash flow was -88.37M and capital expenditures -331,000, giving a free cash flow of -88.70M billion.
- Operating Cash Flow
- -88.37M
- Free Cash Flow
- -88.70M
- Free Cash Flow per Share
- -1.04
Dividends & Yields
Lexeo Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -36.22%
- Earnings Yield
- -34.17%
Stock Price Statistics
- Beta
- 2.31
- 52-Week Price Change
- -65.68%
- 50-Day Moving Average
- 3.56
- 200-Day Moving Average
- 5.06
- Relative Strength Index (RSI)
- 42.19
- Average Volume (3m)
- 1.33M
Important Dates
Lexeo Therapeutics, Inc. upcoming earnings date is Dec 14, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Dec 14, 2026
- Ex-Dividend Date
- ―
Financial Position
Lexeo Therapeutics, Inc. as a current ratio of 11.21, with Debt / Equity ratio of 3.20%
- Current Ratio
- 11.21
- Quick Ratio
- 11.21
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.56
- Interest Coverage Ratio
- -530.37
Taxes
In the past 12 months, Lexeo Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lexeo Therapeutics, Inc. EV to EBITDA ratio is -1.87, with an EV/FCF ratio of -1.79.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.87
- EV to Free Cash Flow
- -1.79
- EV to Operating Cash Flow
- -1.80
Balance Sheet
Lexeo Therapeutics, Inc. has $211.70M in cash and marketable securities with $6.81M in debt, giving a net cash position of $204.89M billion.
- Cash & Marketable Securities
- $211.70M
- Total Debt
- $6.81M
- Net Cash
- $204.89M
- Net Cash Per Share
- $2.50
- Tangible Book Value Per Share
- $2.75
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Lexeo Therapeutics, Inc. is $19.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $19.00
- Price Target Upside
- 557.44% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 64.51%
Scores
- Smart Score
- 4
- AI Score
- 48
